Give me all updates on acs

Asking for Preferences

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive content across definition, epidemiology, pathobiology, diagnosis, risk stratification, and management. Let me compile a thorough, well-structured response.

Acute Coronary Syndrome (ACS) — Comprehensive Overview

Definition & Classification

Acute coronary syndrome (ACS) describes the continuum of myocardial ischemia or infarction. It encompasses three entities, distinguished by ECG findings and troponin levels:

Entity	Chest Pain	Troponin	ST Changes
Unstable Angina (UA)	New, worsening, or rest pain	Negative	None or transient
NSTEMI	Rest or exertional	Positive	ST depression / T-wave inversion (no persistent elevation)
STEMI	Acute onset	Positive	Persistent (>20 min) ST elevation

UA and NSTEMI together are called non-ST elevation ACS (NSTE-ACS).

— Goldman-Cecil Medicine, Ch. 57

Epidemiology

~1.2 million hospitalizations annually in the United States for ACS
~two-thirds are NSTE-ACS
50% of NSTE-ACS patients are older than 65 years; nearly half are women
Higher prevalence with atherosclerosis risk factors, peripheral vascular disease, or chronic inflammatory disorders (rheumatoid arthritis, psoriasis)

— Goldman-Cecil Medicine

Pathobiology

Type 1 MI (most common): Atherosclerotic plaque rupture or erosion → platelet aggregation → thrombus formation → subtotal coronary occlusion → ischemia/infarction.

Type 2 MI: Oxygen supply-demand mismatch without primary plaque rupture:

Supply reduction: hypotension, severe anemia, hypoxemia
Demand surge: tachycardia, severe hypertension, thyrotoxicosis
Other causes: cocaine/methamphetamine use, Prinzmetal vasospasm, spontaneous coronary artery dissection (SCAD — especially in peripartum women), chemotherapy agents, or "triptans"

In Type 2 MI, therapy should target the underlying cause.

— Goldman-Cecil Medicine

Clinical Presentation & Diagnosis

History clues that increase likelihood of ACS:

Older age, diabetes mellitus, extracardiac vascular disease
Chest pain radiating to the left arm, neck, or jaw
Symptoms similar to prior anginal episodes in patients with known CAD

ECG (obtain and interpret within ≤10 minutes):

Persistent ST elevation → initiate reperfusion immediately (STEMI pathway)
ST depression or T-wave inversion in ≥50% of NSTE-ACS
A normal ECG does not exclude ACS (~5% of discharged patients with ACS had a normal initial ECG)
Left circumflex territory ischemia may be missed on standard 12-lead → use posterior leads (V7–V9) or right-sided leads
Deep (>2 mm) symmetrical anterior T-wave inversion → suggests significant LAD or left main stenosis

Biomarkers:

High-sensitivity troponin can detect NSTEMI within 2 hours of symptom onset
Serial troponins are required if initial is normal

— Goldman-Cecil Medicine

Risk Stratification

Key tools include the TIMI and GRACE scores. High-risk features:

Elevated troponin
Dynamic ST changes
Prior PCI or CABG
Hemodynamic instability
Sustained ventricular arrhythmias
Reduced LVEF

High-risk patients benefit from early invasive strategy (within 24 hours); very high-risk (refractory ischemia, cardiogenic shock) within 2 hours.

Management

Anti-Ischemic Therapy

Oxygen: only if SpO₂ <90%
Nitrates: sublingual → IV for ongoing ischemia/hypertension (avoid if hypotension or recent PDE5 inhibitor use)
Beta-blockers: early oral therapy reduces ischemia; IV if refractory ischemia/tachycardia (avoid in decompensated HF, active bronchospasm)
Morphine: cautious use; may mask symptoms and has been associated with adverse outcomes in some registry analyses

Antiplatelet Therapy

Agent	Role
Aspirin 162–325 mg loading → 75–100 mg daily	All ACS patients indefinitely
P2Y₁₂ inhibitors (clopidogrel, ticagrelor, prasugrel)	Dual antiplatelet therapy (DAPT) with aspirin
GP IIb/IIIa inhibitors (eptifibatide, tirofiban, abciximab)	High-risk PCI patients; initiated at time of angiography (not routinely before)

Ticagrelor and prasugrel are more potent than clopidogrel with faster onset; prasugrel is contraindicated in prior stroke/TIA
DAPT is typically maintained for 12 months post-ACS

Anticoagulation

All patients receive anticoagulation unless contraindicated (active bleeding):

Setting	Preferred Agent
Ischemia-guided (non-invasive) strategy	UFH, LMWH, or fondaparinux (lowest bleeding risk)
Invasive strategy (PCI)	UFH or LMWH; bivalirudin during PCI if needed

LMWH (enoxaparin):

1 mg/kg SC twice daily
Superior to UFH in high-risk/biomarker-positive NSTE-ACS
Dose-adjust in obesity (>120 kg), low weight (<60 kg), or CrCl <30 mL/min (target anti-Xa 0.5–1.5 IU/mL)
Avoid in HIT history

UFH: Bolus 60 U/kg IV → infusion ~12 U/kg/hr, titrate to aPTT 50–70 seconds (1.5–2.5× control)

Revascularization

Strategy	Timing
STEMI: primary PCI	<90 min (door-to-balloon)
STEMI if no PCI available	Fibrinolysis within 30 min; transfer for PCI if failed
NSTE-ACS high-risk: early invasive	<24 hours
NSTE-ACS very high-risk	<2 hours
NSTE-ACS low-risk	Ischemia-guided; stress testing may guide decision

Secondary Prevention (Post-ACS)

ACE inhibitor / ARB: especially with reduced EF, hypertension, or diabetes
High-intensity statin: all ACS patients regardless of baseline LDL (target LDL <70 mg/dL; consider <55 mg/dL with ezetimibe or PCSK9 inhibitor if needed)
Beta-blocker: continue long-term (especially with reduced EF)
Aldosterone antagonist: LVEF ≤40% with HF symptoms or diabetes
DAPT for 12 months (duration may vary based on stent type, bleeding risk)
Cardiac rehabilitation

— Goldman-Cecil Medicine, Ch. 57; Braunwald's Heart Disease

Special Considerations

Cocaine/stimulant-induced ACS:

Consider in patients <40 years or with few risk factors
Urine toxicology screen; avoid beta-blockers (unopposed alpha stimulation risk)

CKD and ACS:

ACS is more common and carries higher mortality in CKD patients
LMWH dose adjustment required
Contrast nephropathy risk during angiography must be managed (hydration, minimizing contrast)

SCAD (Spontaneous Coronary Artery Dissection):

Presents as ACS, most often in peripartum women or those with vasculitis
Conservative management often preferred over PCI

Key Points Summary

ACS = UA + NSTEMI + STEMI; distinguished by troponin and ECG
Core mechanism: plaque rupture → thrombus → ischemia/infarction
Diagnosis: ECG within 10 min + serial high-sensitivity troponins
Rx backbone: aspirin + P2Y₁₂ + anticoagulation + early revascularization
STEMI: primary PCI within 90 min is gold standard
NSTE-ACS high-risk: invasive strategy within 24 hours
Long-term: statin + beta-blocker + ACEi/ARB + DAPT + cardiac rehab

All updateson ACS at a deeper and wider level according to AHA including all recent trials please

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

That's a complete deep-dive across all 13 domains. Here's a quick orientation to the content above:

What's covered and what's new vs standard teaching:

Section	Key Updates
§1 Classification	Type 1–5 MI framework now clinically mandatory
§4 Diagnosis	hs-cTn 0h/1h algorithms — rule-out ACS in <2 hours
§6 Antiplatelets	PLATO, TWILIGHT, TRITON — ticagrelor preferred; P2Y₁₂ monotherapy after 1–3 mo now Class IIa
§7 Anticoagulation	AUGUSTUS trial — drop aspirin, keep P2Y₁₂ + OAC in AF post-ACS
§8 Revascularization	COMPLETE trial → complete revascularization now Class I; CULPRIT-SHOCK → culprit-only in cardiogenic shock; radial access Class I
§9 Secondary prevention	Colchicine (COLCOT) Class IIa; PCSK9i Class I; GLP-1 RA and SGLT2i both Class I in T2DM+ASCVD; ARNI post-MI Class IIb
§11 Complications	Structured table with surgical timing
§13 Emerging	Lp(a) lowering agents (pelacarsen, olpasiran) in trials; rivaroxaban 2.5 mg BID post-ACS (ATLAS-ACS 2)

This is a shared conversation. Sign in to Orris to start your own chat.